Table 4.
Number (%) of patients reporting worse, no change, or improved outcomes by treatment
|
Treatment |
Symptom improvement |
Effect of treatment on recovery |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Worse | No change | Improved | p-value | n | Worse | No change | Improved | p-value | |
| Observation only |
1574 |
612 (39) |
507 (32) |
455 (29) |
<0.0001 |
1514 |
264 (17) |
898 (59) |
352 (23) |
<0.0001 |
| IVMP |
1123 |
363 (32) |
192 (17) |
568 (51) |
<0.0001 |
1122 |
145 (13) |
190 (17) |
787 (70) |
<0.0001 |
| Oral corticosteroids |
895 |
301 (34) |
177 (20) |
417 (47) |
<0.0001 |
894 |
116 (13) |
224 (25) |
554 (62) |
<0.0001 |
| Other | 745 | 237 (32) | 160 (21) | 348 (47) | 0.0005 | 740 | 114 (15) | 196 (26) | 430 (58) | <0.0001 |
IVMP, intravenous methylprednisolone.
Oral corticosteroids include oral methylprednisolone, oral dexamethasone, and oral prednisone. Other includes intramuscular adrenocorticotropic hormone, intravenous immunoglobulin, plasmapheresis, and other responses.
p-values are for effect of treatment on outcome from Pearson’s chi-square test; specifically, the p-value for each row compares that row to the distribution in all subjects not in that row.